<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03681080</url>
  </required_header>
  <id_info>
    <org_study_id>17-006</org_study_id>
    <nct_id>NCT03681080</nct_id>
  </id_info>
  <brief_title>Concentration and Attentional Deficits in POTS and Other Autonomic Neuropathies</brief_title>
  <acronym>POTSKog</acronym>
  <official_title>Understanding Impaired Concentration, Attentional Deficits and Their Pathophysiology in Postural Orthostatic Tachycardia Syndrome (POTS) and Other Autonomic Neuropathies (POTSKog-Study Aachen)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with POTS, autoimmune autonomic neuropathy (AAN), pure autonomic failure (PAF), SFN
      and Ehlers Danlos Syndrome (EDS) do not only suffer from orthostatic symptoms such as
      dizziness, headache, neck pain, blurred vision or (pre-) syncope. They also experience
      deficits in attention and concentration (more precisely deficits in selective perspective,
      operating speed, executive functions and memory performance) mainly in upright position. Only
      few studies concerning cognitive impairment in autonomic neuropathies, their frequency,
      aetiology and therapy exist. Many patients concerned, especially with POTS, report attention
      deficits and &quot;brain fog&quot; with problems in their everyday life and work, predominantly in
      upright posture. Specific symptomatic or medical therapies do not exist. Medical treatment
      with Modafinil is discussed and part of a current study at Vanderbilt Autonomic Dysfunction
      Centre (1-5). The investigators want to investigate if problems of concentration, attention
      and/or cognitive dysfunction exist in people with POTS, AAN, SFN and EDS compared to healthy
      controls (HC). Thus the investigators use detailed clinical, autonomic and neuropsychological
      tests in different body positions (lying, sitting and standing) as also acute therapy (leg
      crossing).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cognitive function: Stroop, TMT A und B</measure>
    <time_frame>during intervention (Leg crossing)</time_frame>
    <description>Change of results of cognitive function tests lying compared to standing and leg crossing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure Change (mmHg)</measure>
    <time_frame>during intervention (Leg crossing)</time_frame>
    <description>Change between blood pressure lying compared to compared to standing and leg crossing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart frequency Change (B/min)</measure>
    <time_frame>during intervention (Leg crossing)</time_frame>
    <description>Change between heart frequency lying compared to compared to standing and leg crossing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral blood flow velocity</measure>
    <time_frame>during intervention (Leg crossing)</time_frame>
    <description>Change between cerebral blood flow compared to compared to standing and leg crossing</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Autonomic Failure</condition>
  <condition>Dysautonomia</condition>
  <condition>Cognitive Impairment</condition>
  <condition>Ehlers-Danlos Syndrome</condition>
  <condition>Postural Tachycardia Syndrome</condition>
  <condition>Pure Autonomic Failure</condition>
  <arm_group>
    <arm_group_label>lying</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>cognitive tests are performed during lying in all groups (SFN, AAN, EDS, POTS and controls)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standing</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>cognitive tests are performed during active Standing in all groups (SFN, AAN, EDS, POTS and controls)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>crossed legs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cognitive tests are performed during leg crossing in all groups (SFN, AAN, EDS, POTS and controls)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>leg crossing</intervention_name>
    <description>As Counter maneuvre legs will be crossed and cognitive tests will be performed.</description>
    <arm_group_label>crossed legs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AAN, SFN, hEDS, POTS or healthy control

          -  diagnosis in our clinic on the basis of anamnesis, clinical data as neurological
             examination, tilt table, QST, skin biopsy, norepinephrine values, vitamine B12,
             antibodies

        Exclusion Criteria:

        for all participants

          -  pregnancy, nonage,severe heart insufficiency, deep brain Stimulation, pace maker, drug
             consumption, large fibre polyneuropathy for controls

          -  medication influencing blood pressure, psychiatric disease, synkopes or dizziness,
             neurological disorders esp. polyneuropathy, dementia, vitamine or iron deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Maier, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitiy hospital RWTH Aachen, Department of Neurology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Maier, Dr.</last_name>
    <phone>0241 8085128</phone>
    <email>amaier@ukaachen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joana Schauermann</last_name>
    <phone>0241 8085128</phone>
    <email>jschauermann@ukaachen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital, RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>Nordrhein Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Maier, Dr.</last_name>
      <phone>+49 241 8085128</phone>
      <email>amaier@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Joana Schauermann</last_name>
      <phone>+49 241 8085128</phone>
      <email>jschauermann@ukaachen.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Stewart JM, Del Pozzi AT, Pandey A, Messer ZR, Terilli C, Medow MS. Oscillatory cerebral blood flow is associated with impaired neurocognition and functional hyperemia in postural tachycardia syndrome during graded tilt. Hypertension. 2015 Mar;65(3):636-43. doi: 10.1161/HYPERTENSIONAHA.114.04576. Epub 2014 Dec 15.</citation>
    <PMID>25510829</PMID>
  </results_reference>
  <results_reference>
    <citation>Anderson JW, Lambert EA, Sari CI, Dawood T, Esler MD, Vaddadi G, Lambert GW. Cognitive function, health-related quality of life, and symptoms of depression and anxiety sensitivity are impaired in patients with the postural orthostatic tachycardia syndrome (POTS). Front Physiol. 2014 Jun 25;5:230. doi: 10.3389/fphys.2014.00230. eCollection 2014.</citation>
    <PMID>25009504</PMID>
  </results_reference>
  <results_reference>
    <citation>Arnold AC, Haman K, Garland EM, Raj V, Dupont WD, Biaggioni I, Robertson D, Raj SR. Cognitive dysfunction in postural tachycardia syndrome. Clin Sci (Lond). 2015 Jan;128(1):39-45. doi: 10.1042/CS20140251.</citation>
    <PMID>25001527</PMID>
  </results_reference>
  <results_reference>
    <citation>Gibbons CH, Centi J, Vernino S, Freeman R. Autoimmune autonomic ganglionopathy with reversible cognitive impairment. Arch Neurol. 2012 Apr;69(4):461-6. doi: 10.1001/archneurol.2011.2372. Epub 2011 Dec 12.</citation>
    <PMID>22158721</PMID>
  </results_reference>
  <results_reference>
    <citation>Guaraldi P, Poda R, Calandra-Buonaura G, Solieri L, Sambati L, Gallassi R, Cortelli P. Cognitive function in peripheral autonomic disorders. PLoS One. 2014 Jan 17;9(1):e85020. doi: 10.1371/journal.pone.0085020. eCollection 2014.</citation>
    <PMID>24465471</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2018</study_first_posted>
  <last_update_submitted>September 20, 2018</last_update_submitted>
  <last_update_submitted_qc>September 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Postural Orthostatic Tachycardia Syndrome</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Ehlers-Danlos Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

